Skip to main content

Advertisement

SpringerLink
Log in

The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis

  • Review Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Breast cancer is the most frequent cause of death from cancer in 12 regions of the world. Among the breast cancer subtypes, triple-negative breast cancer (TNBC) is the most aggressive, leading to an adverse prognosis. Thus, we aimed to identify the top 100 most cited articles regarding TNBC through bibliometric analyses, to explore their current impact and publication status. We searched TNBC-related articles from the Web of Science core database on September 19, 2021, and ranked them by citation in descending order. Information extracted from the top 100 most cited articles, included title, author, institution, country, year, publication, Journal Cited Rank, citation, Web of Science category, were extracted by two researchers independently. VOSviewer was used to analyze data, such as co-authoring institutions, and author cooperation. Descriptive statistical analysis of data was performed using Excel. Citations from the top 100 most cited articles ranged from 225 to 2753, and all were published after 2007. The top 100 most cited articles were published in 38 journals, with the Journal of Clinical Oncology published the most (n = 15), followed by Clinical Cancer Research (n = 11), Lancet Oncology(n = 6). Eric P. Winer from USA, who participated 12 articles, was the most frequently published author. The USA (n = 71) was the country with the most contributions to TNBC. The most prevalent topics included: clinical features, molecular subtypes, relevant influencing factors, exploration of treatment options and prognosis of TNBC. The leading institution was the Dana Farber Cancer Institute (n = 20) from the USA. This is the first bibliometric analysis on the TNBC 100 most cited article. We provided insights into the most cited articles on TNBC and listed a detailed description of their characteristics and trend, which provides ideas for further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

source: World health organization, globocan 2020

Similar content being viewed by others

Abbreviations

TNBC:

Triple-negative breast cancer

BL1:

Basal-like

BL2:

Basal-like 2

M:

Mesenchymal,

MSL:

Mesenchymal stem-like

IM:

Immunomodulatory,

LAR:

Luminal androgen receptor,

ER:

Estrogen receptor

PR:

Progesterone receptor

HER2:

Human epidermal growth factor receptor2

JCR:

Journal Citation Reports

IF:

Impact factor

pCR:

Pathological response rates

GE:

Gene expression

BRCA:

Breast cancer susceptibility gene,

PD-L1:

Programmed Cell Death-Ligand 1

ORR:

Overall response rate

HSP 90:

Heat shock protein 90

HDAC:

Histone deacetylase

RD:

Residual disease

References

  1. Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18(10):663–72. https://doi.org/10.1038/s41571-021-00514-z.

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  3. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588.

    Article  PubMed  Google Scholar 

  4. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303.

    Article  CAS  Google Scholar 

  5. Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med. 2020;8(7):499. https://doi.org/10.21037/atm.2020.03.194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–61. https://doi.org/10.3892/ijo.2020.5135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res BCR. 2020;22(1):61. https://doi.org/10.1186/s13058-020-01296-5.

    Article  PubMed  Google Scholar 

  8. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(15 Pt 1):4429–34. https://doi.org/10.1158/1078-0432.CCR-06-3045.

    Article  Google Scholar 

  9. Cocco S, Piezzo M, Calabrese A, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci. 2020;21(13):E4579. https://doi.org/10.3390/ijms21134579.

    Article  CAS  Google Scholar 

  10. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98. https://doi.org/10.1158/2159-8290.CD-18-1177.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. He MY, Rancoule C, Rehailia-Blanchard A, et al. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96–101. https://doi.org/10.1016/j.critrevonc.2018.09.004.

    Article  PubMed  Google Scholar 

  12. Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers. 2020;12(4):E916. https://doi.org/10.3390/cancers12040916.

    Article  CAS  Google Scholar 

  13. Devos P, Menard J. Bibliometric analysis of research relating to hypertension reported over the period 1997–2016. J Hypertens. 2019;37(11):2116–22. https://doi.org/10.1097/HJH.0000000000002143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhao H, Liu JB, Bao ZF, Xu YX, Wang ZQ. Global research trends in dental stem cells: a bibliometric and visualized study. Tissue Eng Part B Rev. 2021. https://doi.org/10.1089/ten.TEB.2021.0080.

    Article  PubMed  Google Scholar 

  15. Li M, Cai Q, Ma JW, Zhang L, Henschke CI. The 100 most cited articles on lung cancer screening: a bibliometric analysis. Ann Transl Med. 2021;9(9):787. https://doi.org/10.21037/atm-20-3199.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ahn SK, Hwang JW. Global trends in immunotherapy research on breast cancer over the past 10 years. J Oncol. 2020;2020:4708394. https://doi.org/10.1155/2020/4708394.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gao Y, Shi S, Ma W, et al. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. Int Immunopharmacol. 2019;72:374–84. https://doi.org/10.1016/j.intimp.2019.03.045.

    Article  CAS  PubMed  Google Scholar 

  18. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. https://doi.org/10.1172/JCI45014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jaffe K, Ter Horst E, Gunn LH, Zambrano JD, Molina G. A network analysis of research productivity by country, discipline, and wealth. PLoS ONE. 2020. https://doi.org/10.1371/journal.pone.0232458.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Inernational agency for research on cancer. Estimated age-standardized incidence rates (World) in 2020, breast, females, all ages. Global Cancer Observatory. Published online August 5, 2021. https://gco.iarc.fr/.

  21. Bauer et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor.pdf. 2007.

  22. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. https://doi.org/10.1038/nrclinonc.2016.66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9. https://doi.org/10.1038/nature10933.

    Article  CAS  PubMed  Google Scholar 

  24. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389.

    Article  CAS  PubMed  Google Scholar 

  25. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549.

    Article  CAS  PubMed  Google Scholar 

  26. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(21):2460–7. https://doi.org/10.1200/JCO.2015.64.8931.

    Article  CAS  Google Scholar 

  27. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(3):397–404. https://doi.org/10.1093/annonc/mdy517.

    Article  CAS  Google Scholar 

  28. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–21. https://doi.org/10.1056/NEJMoa1809615.

    Article  CAS  PubMed  Google Scholar 

  29. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. https://doi.org/10.1016/S1470-2045(19)30689-8.

    Article  CAS  PubMed  Google Scholar 

  30. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/JCO.2007.14.4147.

    Article  Google Scholar 

  31. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(8):2329–34. https://doi.org/10.1158/1078-0432.CCR-06-1109.

    Article  CAS  Google Scholar 

  32. Didion CA, Henne WA. A Bibliometric analysis of folate receptor research. BMC Cancer. 2020;20:1109. https://doi.org/10.1186/s12885-020-07607-5.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ahmad P, Slots J. A bibliometric analysis of periodontology. Periodontol 2000. 2021;85(1):237–40. https://doi.org/10.1111/prd.12376.

    Article  PubMed  Google Scholar 

  34. Brandt JS, Hadaya O, Schuster M, Rosen T, Sauer MV, Ananth CV. A bibliometric analysis of top-cited journal articles in obstetrics and gynecology. JAMA Netw Open. 2019;2(12): e1918007. https://doi.org/10.1001/jamanetworkopen.2019.18007.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors have not disclosed any funding.

Author information

Author notes

  1. Yuyan Huang and Peiyun Chen: Share the first authorship.

Authors and Affiliations

  1. School of Nursing, Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Yuyan Huang, Bo Peng & Ruyu Liao

  2. Endocrinology, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, People’s Republic of China

    Peiyun Chen

  3. Nursing Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Houqiang Huang, Qi Chen, Shengmin Guo & Silin Zheng

  4. Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Min Huang

  5. Breast Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Shizhen Li

Authors
  1. Yuyan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peiyun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruyu Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Houqiang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shizhen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shengmin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Silin Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SZ, SG and SL designed this study, YH and BP performed the search and extracted the data. PC and RL re-checked the data. YH performed data analysis, HH revised it. YH wrote the manuscript, and MH and QC reviewed the manuscript.

Corresponding author

Correspondence to Silin Zheng.

Ethics declarations

Conflict of interest

No potential conflict of interest was reported.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Y., Chen, P., Peng, B. et al. The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis. Clin Exp Med 23, 175–201 (2023). https://doi.org/10.1007/s10238-022-00800-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00800-9

Keywords

Search

Navigation